Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
GSK Vows to Ensure Proper Use of Shingles Jab towards NIP Inclusion
GlaxoSmithKline is set to step up its communication activities to ensure the proper use of its shingles vaccine Shingrix, which will be included in Japan’s national immunization program (NIP) from April. At a press seminar on February 28, Taro Kunitomi,…
To read the full story
Related Article
- Shingles Shots Added to NIP, HPV Catch-Up Program Extended: MHLW
April 7, 2025
- GSK’s Shingrix Buttresses Label with Long-Term Data
April 2, 2025
- GSK Applauds Japan’s Plan to Include Shingles Vaccines in NIP
December 19, 2024
- Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
December 19, 2024
BUSINESS
- Lilly Japan Names Karla Alcazar as New President
June 22, 2026
- Shionogi’s CEO Pay Up at 302 Million Yen in FY2025
June 22, 2026
- J-TEC Sets Up German Unit to Expand LabCyte Biz in Europe
June 22, 2026
- Daiichi Sankyo CEO’s Pay Rises to 273 Million Yen in FY2025
June 22, 2026
- Shionogi/F2G’s Novel Antifungal Makes Mark, New Option in Resistant Cases
June 19, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…